These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9352329)

  • 1. A case of veno-occlusive disease complicated by severe hemorrhagic cystitis successfully treated with recombinant plasminogen activator.
    Arsène O; Delain M; Linassier C; Bremond JL; Colombat P
    Hematol Cell Ther; 1997 Aug; 39(4):205-7. PubMed ID: 9352329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
    Baglin TP; Harper P; Marcus RE
    Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.
    Yu LC; Malkani I; Regueira O; Ode DL; Warrier RP
    Am J Hematol; 1994 Jul; 46(3):194-8. PubMed ID: 8192148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
    Terra SG; Spitzer TR; Tsunoda SM
    Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
    Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
    Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation.
    Hágglund H; Ringdén O; Ericzon BG; Duraj F; Ljungman P; Lönnqvist B; Winiarski J; Tydén G
    Transplantation; 1996 Oct; 62(8):1076-80. PubMed ID: 8900305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
    Goldberg SL; Shubert J; Rao AK; Redei I; Klumpp TR; Mangan KF
    Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
    Heying R; Nürnberger W; Spiekerkötter U; Göbel U
    Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?
    Yoon JH; Min WS; Kim HJ; Kim JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Park CW
    Bone Marrow Transplant; 2013 Nov; 48(12):1562-8. PubMed ID: 23892329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR; Browett PJ; Doak PB; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
    Sonneveld P; Laméris JS; Cornelissen J; Ogilvie A; Löwenberg B
    Bone Marrow Transplant; 1998 Apr; 21(7):731-4. PubMed ID: 9578316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation.
    Bearman SI; Shuhart MC; Hinds MS; McDonald GB
    Blood; 1992 Nov; 80(10):2458-62. PubMed ID: 1421368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment.
    Espigado I; Rodríguez JM; Parody R; Carmona M; Digón J; Olloqui E
    Bone Marrow Transplant; 1995 Aug; 16(2):313-6. PubMed ID: 7581155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
    Lee JH; Lee KH; Lee JH; Kim S; Seol M; Park CJ; Chi HS; Kang W; Kim ST; Kim WK; Lee JS
    Br J Haematol; 2002 Sep; 118(4):1087-94. PubMed ID: 12199790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients.
    Bearman SI; Lee JL; Barón AE; McDonald GB
    Blood; 1997 Mar; 89(5):1501-6. PubMed ID: 9057629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
    Leahey AM; Bunin NJ
    Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.